Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Agnieszka Warszewska"'
Autor:
Andrea Janíková, Jan Walewski, Thomas Herz, Babett Krauss, Ewa Paszkiewicz-Kozik, Gabriela Borsaru, Andrzej Hellmann, Stefan W. Henning, Agnieszka Warszewska, A. Mais, Astrid S. Ammendola
Publikováno v:
Leukemialymphoma. 60(3)
This open-label, single-arm phase II study examined efficacy, safety, pharmacokinetics, and biomarkers of histone deacetylase (HDAC) inhibitor resminostat in patients with relapsed or refractory Hodgkin lymphoma. Thirty-seven heavily pretreated patie
Autor:
A. Mais, Jan Walewski, Gabriela Borsaru, B. Hauns, Bernd Hentsch, Ewa Paszkiewicz-Kozik, Andreea Moicean, Jiri Mayer, Stefan W. Henning, Agnieszka Warszewska, Andrzej Hellmann
Publikováno v:
Blood. 118:2675-2675
Abstract 2675 Background: Resminostat is an oral pan-histone deacetylase (HDAC) inhibitor that has shown anti-tumor activity in a broad panel of preclinical models and revealed a favorable safety and efficacy profile in a first-in-man phase I study i
Autor:
Agnieszka Warszewska, Gabriela Borsaru, Alberto Biggi, Andreea Moicean, Jan Walewski, Bernd Hentsch, B. Hauns, A. Mais, Klaus Strobel, Stefan W. Henning, Ewa Paszkiewicz-Kozik
Publikováno v:
Blood. 116:2811-2811
Abstract 2811 Resminostat (4SC-201) is a novel pan-HDAC inhibitor that has shown anti-tumor activity in a broad panel of preclinical models and revealed a very favorable safety and promising efficacy profile in patients with various solid tumor types